Enhancing PR&MA decision making by combining cutting edge tools with proven field expertise to harness complexity in healthcare
'World class work delivered within very tight timelines' –
Vice President Europe Commercial Operations,
global specialty pharma company
Access to good public healthcare at sustainable prices is crucial to patients, providers and payors alike.
Akceso Advisors is your partner to maximise market access for your products, whether you are launching an innovative medicine, a generic drug or managing the lifecycle of a therapy. We have a proven track record of improving patient health through understanding and clearly articulating provider and payor needs. We create the right strategy to deliver rationally-priced medicines and devices. We have a wealth of experience in solving product access challenges across therapeutic areas in over 60 countries.
Akceso is a specialist pricing, reimbursement & market access consultancy. Headquartered in Basel, Switzerland, Akceso is directly represented through a worldwide network of advisors.
'The market assessment project provided very good, value-adding outcomes delivered on time within very tight timelines. Akceso looked at an unclear situation, analysed and framed it and drew conclusions and practical recommendations. Akceso also developed very practical tools beyond our original expectations, to support our own follow-up activities' –
Director Market Access & Commercial Effectiveness,
Novo Nordisk International
WORLD P&R NEWS HIGHLIGHTS
Akceso produces a monthly newsletter covering recent developments in Pricing, Reimbursement & Market Access. To subscribe, send a request to email@example.com
AKCESO RECENT NEWS
21st January 2017: Akceso mentoring UK young entrepreneurs.
Akceso is proud to be supporting UK innovation. Chris Shilling is a mentor for teams in the annual Biostars competition. See the Biostars web site for more information.
(for daily news please go to Akceso's Twitter Page)
Feb 7th US Rx drug prices up nearly 11% in 2017
Express Scripts, the largest U.S. pharmacy benefits manager (PBM), calculations show brand-name list price increases in 2016 were nearly 11%.
Jan 31st - Europe faces steep price increases for some old cancer drugs
European prices for some off-patent cancer drugs have risen by more than 100 percent in the past five years, with two cases of hikes exceeding 1,000 percent, according to data presented at a recent medical conference.
|phone:||+41 61 225 4393|
|Akceso Advisors AG